Ari Johnson

Ari Johnson, MD, is co-founder and CEO of Muso, and Associate Professor at the University of California San Francisco, in the Department of Medicine and the Institute for Global Health Sciences. The co-recipient of the 2021 Charles Bronfman Prize, Ari trained at Harvard Medical School and completed his residency at the University of California San Francisco. He has published peer-reviewed articles and essays in the fields of infectious disease, health systems design, socioeconomic determinants of health, AIDS, and migration.

Over the past fifteen years, Ari has supported Muso to design and build Proactive Community Case Management, a strategy for rapid, universal access to care. A 2018 study in BMJ Global Health documented how communities served by this strategy achieved and sustained a rate of child death lower than any country in Sub-Saharan Africa for five years running.

Following up on these findings, in November 2023, a consortium of researchers announced the results of the ProCCM Trial, which followed more than 135,000 people across 137 sites in rural Mali. Muso currently cares for more than 500,000 patients, and supports the governments of Mali and Côte d’Ivoire to redesign their national community health systems.